Pregnant, planning a pregnancy or breast feeding during the study
Pregnant, lactating, or planning to become pregnant during the study and up to  months after last dose of study drug
Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for  months after last dose of talimogene laherparepvec
Females who are pregnant, breast-feeding, or planning to become pregnant within  months after the last dose of study drug and males who plan to father a child while enrolled in this study or within  months after the last dose of study drug
Pregnant, planning a pregnancy, or breast feeding
Patients who are breastfeeding, pregnant, or planning to become pregnant from the time of informed consent until  months after the final study dose is administered
If female, is pregnant, breastfeeding, or planning to become pregnant.
Female subjects who are pregnant or breastfeeding or planning to become pregnant or breastfeed, or of childbearing potential unwilling to use an effective method of contraception while receiving, and for an additional  hours after the last dose of blinatumomab.
A woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within  months after the last dose of study drug
Patients who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.
If female, is pregnant, breastfeeding, or planning to become pregnant.
Women planning to become pregnant while on study through  week after receiving the last dose of study drug
Pregnant or planning to become pregnant during period of study participation
Subject who is pregnant (as confirmed by pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding; and
Pregnant, breast feeding, or planning to become pregnant
Females who are pregnant or breastfeeding or planning to become pregnant within  days after their last anticipated dose of BCV
A woman who is pregnant or breast-feeding, or a woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within  months after the last dose of study agent
Female subjects who are pregnant, are planning on becoming pregnant, or are currently breastfeeding.
Breast-feeding at screening or planning to become pregnant during the course of therapy
Subject is pregnant or breast feeding, or planning to become pregnant within  months after the end of treatment
Female subject is pregnant or breast-feeding, or planning to become pregnant or male subject is planning to father a child within the projected duration of the trial, starting with the pre-screening or screening visit, during study treatment and through  months after the last dose of talimogene laherparepvec or  months after the last dose of pembrolizumab, whichever is later
Women who are pregnant or breast-feeding currently or are planning to do so during or up to  months after the end of protocol therapy.
Subject is pregnant or breast feeding, or planning to become pregnant/breastfeed while on study through  months after the end of treatment
Females who are pregnant, breastfeeding, or planning a pregnancy during the treatment period or within  months after the last infusion of study drug.
Breast-feeding at screening or planning to become pregnant during the course of therapy
Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through  months after the last dose of study treatment
Pregnancy, breast-feeding or planning to become pregnant
Female subjects who are pregnant or planning to become pregnant during the course of SABR
Women who are planning to become pregnant or breast feed during the trial
Patient is pregnant, lactating, or planning on being pregnant within the next  months
Pregnant or lactating or planning pregnancy during treatment period.
 Females planning to become pregnant while on study through  days after receiving the last dose of study drug.
Female of child bearing potential who is pregnant, is planning to become pregnant, or is breast feeding; or male who is sexually active with a female of child bearing potential who is planning to become pregnant.
Female patients who are pregnant, breast-feeding, or planning to become pregnant
Pregnant, planning to become pregnant, or breast feeding.
Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within  months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within  months after the last dose of any component of the treatment regimen
Pregnant or breastfeeding, or planning to become pregnant within  months after the end of treatment
Subject is pregnant or breast feeding, or planning to become pregnant within  months after the end of treatment
Pregnant, planning to become pregnant, or nursing
Pregnant, planning to become pregnant, or nursing
Pregnancy, or planning to become pregnant
Women planning to become pregnant or who are lactating/breastfeeding while on study through  months after receiving the last dose of study drug.
Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed while receiving blinatumomab and for an additional  hours after the last treatment dose of blinatumomab.
Be pregnant, planning a pregnancy, or breastfeeding
Patients planning to take a vacation for  or more consecutive days during the course of the study.
Currently pregnant or breast-feeding, or planning to become pregnant during study treatment and through  months after the last dose of study treatment
Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
Is pregnant, breastfeeding, or planning a pregnancy
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through  months after the last dose of talimogene laherparepvec
Subjects who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.
Patients who are currently pregnant, planning to become pregnant, or breast-feeding
Patient is pregnant or breast feeding, or planning to become pregnant within  months after the end of treatment
Currently pregnant or nursing, or planning pregnancy (in the period up to  months) following the index procedure(s),
Subject is pregnant or breast feeding, or planning to become pregnant within  months after the end of treatment.
The participant is pregnant, breastfeeding, or planning to become pregnant or father a child
Pregnant, nursing or planning to become pregnant
Subject is currently pregnant or breastfeeding, or is planning to become pregnant during the study
Patient is a female who is pregnant, lactating, or is planning a pregnancy during study participation, or in the follow-up period.
Pregnant, breastfeeding, or planning to become pregnant during the study;
Pregnant or planning to become pregnant
Pregnancy or planning to become pregnant
Is pregnant, breastfeeding, or planning a pregnancy
Pregnant, lactating or planning to become pregnant
Females in the study must not be pregnant or breast feeding and not planning to become pregnant or breast feed for the duration of the study, and for at least three months after study completion
Women who are lactating/breastfeeding or planning to become pregnant during the duration of the study
Subject is pregnant or breast feeding, or planning to become pregnant within  months after the end of treatment
Pregnant or breast-feeding, or planning to become pregnant during study treatment and within  months after the last administration of investigational product.
Female patients who are pregnant or breast-feeding are not eligible; NOTE: A woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within  months after the last dose of study agent should likewise not be considered for this study
Female subjects who are pregnant, or breastfeeding, or planning to become pregnant. Male subjects who plan to father a child while enrolled in this protocol.
Subject is pregnant, nursing, or planning to get pregnant during study duration.
Those who are currently pregnant, have been pregnant within the last  months, or are planning to become pregnant in the next  months.
Patient is pregnant, breastfeeding, has given birth within the last  months or planning pregnancy within the next  months; if participant becomes pregnant during the course of the study, she will be removed from further participation
Not currently pregnant or planning to become pregnant throughout the duration of cancer treatment
Negative se rum pregnancy test and not planning to be pregnant in the next  months
A positive pregnancy test, currently pregnant or planning to become pregnant in the next three months
Currently pregnant, nursing or planning to become pregnant
Currently pregnant or planning to become pregnant
Subject is pregnant or breast feeding, or planning to become pregnant within  months after end of treatment
Women who are pregnant or breastfeeding or planning to become pregnant or breastfeed during the period of treatment and for  days following the last dose of sotatercept
Self-report that they are not pregnant or planning to become pregnant in the next four months
Pregnant or planning to become pregnant during the course of the study
Not pregnant or planning on becoming pregnant
Patient is a woman with a positive serum pregnancy test at screening, is pregnant, breast-feeding, or is planning to conceive children within the projected duration of the study treatment
Are planning to conceive or are currently pregnant or lactating
Women who are breastfeeding, pregnant, or planning pregnancy within the next year
Pregnant or planning to become pregnant within the next year
Patients who are pregnant, planning pregnancy, or breast feeding
Being pregnant or planning on becoming pregnant within the next year
Women who are pregnant or lactating, or planning pregnancy while enrolled in the study or for  months after the last dose of the study drug
Pregnant, planning to become pregnant starting from  days prior to receiving CC- throughout your participation in the study, and for at least  days following your last dose of study treatment, or breast-feeding females
Women who are pregnant, planning pregnancy within the next year, or lactating/breastfeeding
Female planning to become pregnant or planning to discontinue contraceptive precautions before Month  (i.e.,  months after the last dose of study vaccine/placebo).
A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose.
Subjects who have contraindications for receiving Y- therapy and any routine procedures and imaging associated with Y- therapy, including subjects who are pregnant or are planning to become pregnant, will not be eligible to participate in this study. Female subjects who are of childbearing potential should inform her treating physician should she become pregnant at any time during the course of the study
Women who are pregnant or planning to become pregnant during the trial
Patients who are pregnant, breast-feeding or are planning to become pregnant during the study duration
Pregnant or breastfeeding, or planning to become pregnant.
For female participants: being pregnant or breastfeeding, or planning to become pregnant, by self-report
Pregnancy and contraception: Subjects who are pregnant, breast-feeding or planning to conceive within  days are not eligible
Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study.
not pregnant, breastfeeding, or planning to become pregnant
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit
Female subject who is pregnant or breastfeeding, or planning to become pregnant within  days after ending treatment
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through  months after the last dose of talimogene laherparepvec.
Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit